Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma
International Journal of Clinical Oncology · 2026-07 · 31 (7) · 1137-1150
DOI: 10.1007/s10147-026-03062-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 12.06.2026. Verfasst von Kana Miyazaki. Beteiligte Einrichtung: Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. kmiyazaki@med.mie-u.ac.…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mie University.
Abstract (Originalsprache)
Despite recent progress in improving patient survival, the outcomes in approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) remain poor. For many years, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard first-line treatment for DLBCL; however, pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) has recently emerged as a new treatment option. In parallel, novel molecularly targeted therapies that target signaling pathways, cellular antigens, and epigenetic regulators associated with high-risk DLBCL are in development. Treatment strategies tailored to the cell of origin or to specific molecular subtypes are also being explored using subtype-specific targeted agents. In addition, agents that have demonstrated efficacy in patients with relapsed or refractory DLBCL—such as the anti-CD19 antibody tafasitamab and immunomodulatory drugs such as golcadomide—are currently under investigation for use in newly diagnosed patients. Immunotherapies, including anti-CD19-chimeric antigen receptor-T therapy and CD20×CD3 bispecific antibodies (BsAbs), have significantly improved outcomes in patients with relapsed or refractory disease and are now under evaluation as early-line therapies. BsAbs can enable more flexible treatment strategies, including combination regimens with cytotoxic or chemotherapy-free approaches. This review summarizes recent advances and ongoing trials that are investigating novel therapeutic strategies for newly diagnosed DLBCL that may soon be incorporated into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. kmiyazaki@med.mie-u.ac.jp.
Förderung
- Mie University
Zitieren
APA
Miyazaki, K. (2026). Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma. International Journal of Clinical Oncology, 31(7), 1137-1150. https://doi.org/10.1007/s10147-026-03062-7
Vancouver
Miyazaki K. Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma. International Journal of Clinical Oncology. 2026;31(7):1137-1150. doi:10.1007/s10147-026-03062-7
BibTeX
@article{Miyazaki2026,
author = {Miyazaki, Kana},
title = {Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {7},
pages = {1137--1150},
doi = {10.1007/s10147-026-03062-7}
}
EUVIMED